Gilead Sciences: About to start trials of an inhaled version of Remdesivir
|Gilead Sciences CEO in a statement announced on Monday that the company is about to start trials of an inhaled version of its experimental coronavirus treatment drug Remdesivir.
Key takeaways
"Will screen healthy volunteers for phase 1 trials this week and hope to begin studies in patients with COVID-19 in August."
"Now expect to have more than two million Remdesivir treatment courses manufactured by the end of the year and many millions more by 2021."
"Also exploring whether it can improve patient outcomes by combining Remdesivir with other therapies."
Market reaction
The market mood remains upbeat following these remarks and the greenback is struggling to find demand as a safe-haven. As of writing, the US Dollar Index was down 0.37% on the day at 97.30.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.